Aoxin Q&M Dental Group (SGX:1D4) recently completed its Initial Public Offering (IPO) less than a month ago to join the SGX Catalist with proposed listing of 57 million new shares at $0.20 each entirely via private placement.
It eventually opened at 23 cents per share, 3.0 cents higher than its IPO price. The latest price (11 May 8:50a) is 25.5 cents per share.
You can check out the offering document here. Here are five key points Small Cap Asia highlighted for investors interested in the stock.
1. Aoxin’s Company Profile
As you can see from the name, Aoxin is spun off from its parent – Q&M Dental Group to tap the rising demand from China. Here’s what I obtained from the offer doc (in my words):
Aoxin is one of the leading providers of private dental services and dental equipment and supplies in the Liaoning Province, Northern PRC.
As at the Latest Practicable Date, Aoxin has 240 dental professionals, comprising 113 dentists and 127 dental surgery assistants.
They operate and manage 11 dental centres, comprising four dental hospitals and seven polyclinics.
The centres are located in four different cities in Liaoning Province, Northern PRC, namely, Shenyang, Huludao, Panjin and Gaizhou.
Additionally, Aoxin also owns a dental equipment and supplies distribution network, which covers the Liaoning, Heilongjiang and Jilin Provinces in the Northern PRC.
In short, Aoxin’s core business can be categorised into two business segments:
- Providing private dental services & management of dental centres for and on behalf of other owners
- Distribution of dental equipment and supplies.
2. IPO Details
Following the placement, Aoxin will have a market cap of S$71.2 million.
Q&M (SGX: QC7) will retain a 45.9-percent stake while its executive director and chief executive Shao Yongxin will hold a 30.08-percent stake.
Taken from Offer Document
As you can see, the bulk of funds raised – S$6.4 million (70.3 percent) of net proceeds would go into an expansion of its business.
The remaining amount of S$2.7 million (29.7 percent) is set aside for “enhancement of infrastructure and working capital purposes”.
The company has seen explosive growth over the three-year period from FY2013-2015.
Revenue skyrocketed from Rmb0.5m to Rmb46.5m, underpinned by strong M&A activity, as well as increased patient visitorship.
It also turned around from a Rmb4.1m loss in FY13 to a Rmb4.8m profit in FY15.
In the latest 9M16 results, core net profit jumped to Rmb4.9m (+148 percent) on an 85-percent surge in revenue to Rmb61.5m.
A huge portion of the sales growth can be attributed to 3 big reasons:
- maiden contribution from dental equipment and supplies distributor SY Maotai, purchased in Jan ’16
- Acquisition of five dental centres in Panjin and Gaizhou
- Organic growth from existing dental centres.
4. Growth Prospects
According to independent market research consultancy Technavio, Q & M Dental Group has been established as one of the top five vendors in China’s dental services market.
The market is expected to grow at a CAGR of 18 percent from 2016 to 2020.
Dental care in China is still in its infancy. This is projected to change shortly, as living standards are rising and awareness of dental health issues has increased.
- Western countries: 500-1000 dentists to 1mil population.
- Singapore: 500 dentists to 1mil population
- China: only 100 dentists to 1mil population
One thing I like about Aoxin is how it has collaborated with the Jinzhou Medical University to provide training to dental professionals.
While addressing the bottleneck in the supply of dentists, Aoxin’s image or reputation is also enhanced and recognised.
“In Singapore, our dentists are sent to Singapore National Dental Centre for post-graduate training. Aoxin has capabilities that parallel Singapore National Dental Centre in this aspect,” said Q & M Dental Group COO Raymond Ang.
Overall, there is rapidly growing demand for accredited dental centres in China. This is because of the rise in corporate staff entitled for public medical insurance.
For example, you work for company ABC, and as part of its benefits program, it gives you say $500 to visit Aoxin Q&M annually.
That’s an excellent recurring source of income for Aoxin isn’t it!?
Despite all the good things you heard, Aoxin is based in China. Thus, it is “subject to strict regulations for our operations and changes in government policies relating to health care reforms”.
Its business may be affected if the dental centres lose their accreditation or if there are any changes to the Chinese public health insurance programmes.
Furthermore, it is listing at a high P/E of 37.7x based on the FY2015 EPS. This valuation is around the same as other healthcare companies like Raffles Medical etc.
But given its strong niche market in dental healthcare, I do think that it has much room to grow in future.